VI

Vigilant Biosciences

- PRIVATE:VIGILANTBIOSCIENCES
For additional historical data visit
thinknum.com/demo

Overview

Datasets

LinkedIn Profile Data

Request demo
# Ticker Symbol Entity Name As Of Date Company Name Followers Employees on Linkedin Link Industry Date Added Date Updated Description Website Specialities Logo HQ.Street HQ.City HQ.State HQ.Country HQ.Postal Ticker Sector Ticker Industry
1 private:vigilantbiosciences 9016939 Mar 18th, 2019 12:00AM Vigilant Biosciences, Inc. 679 12.00 Open Biotechnology Mar 18th, 2019 12:00AM Mar 18th, 2019 01:03PM Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert® Oral Cancer and OncAlert® Labs product lines include point-of-care and lab-based products that are simple, accurate and cost-effective, and empower healthcare practitioners to improve lives through earlier intervention. The Vigilant Biosciences product line is based on patented technology that measures an unprecedented combination of CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer. The simple, oral rinse procedure is easy to administer and non-invasive for the patient. The OncAlert product line currently includes the OncAlert Labs OraMark Test, the OncAlert Oral Cancer RAPID Test, and the OncAlert Oral Cancer LAB Test. The OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test are both CE Marked and available in select markets outside the United States. OraMark is a laboratory-developed test and will be available in the United States through OncAlert Labs, a CLIA certified laboratory, starting in 2016. Leadership: Matthew H.J. Kim, J.D., Founder Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Sally Bowden, Vice President, Regulatory Affairs, Quality Assurance and Operations Robert T. Hamilton, CPA, Chief Financial Officer Open Biotechnology, Oncology, Diagnostics Open 6301 NW 5th Way, Suite 1550 Ft. Lauderdale FL US 33309 Health Care Equipment & Services
2 private:vigilantbiosciences 9016939 Mar 17th, 2019 12:00AM Vigilant Biosciences, Inc. 679 12.00 Open Biotechnology Mar 17th, 2019 12:00AM Mar 17th, 2019 07:52PM Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert® Oral Cancer and OncAlert® Labs product lines include point-of-care and lab-based products that are simple, accurate and cost-effective, and empower healthcare practitioners to improve lives through earlier intervention. The Vigilant Biosciences product line is based on patented technology that measures an unprecedented combination of CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer. The simple, oral rinse procedure is easy to administer and non-invasive for the patient. The OncAlert product line currently includes the OncAlert Labs OraMark Test, the OncAlert Oral Cancer RAPID Test, and the OncAlert Oral Cancer LAB Test. The OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test are both CE Marked and available in select markets outside the United States. OraMark is a laboratory-developed test and will be available in the United States through OncAlert Labs, a CLIA certified laboratory, starting in 2016. Leadership: Matthew H.J. Kim, J.D., Founder Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Sally Bowden, Vice President, Regulatory Affairs, Quality Assurance and Operations Robert T. Hamilton, CPA, Chief Financial Officer Open Biotechnology, Oncology, Diagnostics Open 6301 NW 5th Way, Suite 1550 Ft. Lauderdale FL US 33309 Health Care Equipment & Services
3 private:vigilantbiosciences 9016939 Mar 16th, 2019 12:00AM Vigilant Biosciences, Inc. 679 12.00 Open Biotechnology Mar 16th, 2019 12:00AM Mar 16th, 2019 02:56AM Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert® Oral Cancer and OncAlert® Labs product lines include point-of-care and lab-based products that are simple, accurate and cost-effective, and empower healthcare practitioners to improve lives through earlier intervention. The Vigilant Biosciences product line is based on patented technology that measures an unprecedented combination of CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer. The simple, oral rinse procedure is easy to administer and non-invasive for the patient. The OncAlert product line currently includes the OncAlert Labs OraMark Test, the OncAlert Oral Cancer RAPID Test, and the OncAlert Oral Cancer LAB Test. The OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test are both CE Marked and available in select markets outside the United States. OraMark is a laboratory-developed test and will be available in the United States through OncAlert Labs, a CLIA certified laboratory, starting in 2016. Leadership: Matthew H.J. Kim, J.D., Founder Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Sally Bowden, Vice President, Regulatory Affairs, Quality Assurance and Operations Robert T. Hamilton, CPA, Chief Financial Officer Open Biotechnology, Oncology, Diagnostics Open 6301 NW 5th Way, Suite 1550 Ft. Lauderdale FL US 33309 Health Care Equipment & Services
4 private:vigilantbiosciences 9016939 Mar 15th, 2019 12:00AM Vigilant Biosciences, Inc. 679 12.00 Open Biotechnology Mar 15th, 2019 12:00AM Mar 15th, 2019 02:00AM Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert® Oral Cancer and OncAlert® Labs product lines include point-of-care and lab-based products that are simple, accurate and cost-effective, and empower healthcare practitioners to improve lives through earlier intervention. The Vigilant Biosciences product line is based on patented technology that measures an unprecedented combination of CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer. The simple, oral rinse procedure is easy to administer and non-invasive for the patient. The OncAlert product line currently includes the OncAlert Labs OraMark Test, the OncAlert Oral Cancer RAPID Test, and the OncAlert Oral Cancer LAB Test. The OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test are both CE Marked and available in select markets outside the United States. OraMark is a laboratory-developed test and will be available in the United States through OncAlert Labs, a CLIA certified laboratory, starting in 2016. Leadership: Matthew H.J. Kim, J.D., Founder Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Sally Bowden, Vice President, Regulatory Affairs, Quality Assurance and Operations Robert T. Hamilton, CPA, Chief Financial Officer Open Biotechnology, Oncology, Diagnostics Open 6301 NW 5th Way, Suite 1550 Ft. Lauderdale FL US 33309 Health Care Equipment & Services
5 private:vigilantbiosciences 9016939 Mar 14th, 2019 12:00AM Vigilant Biosciences, Inc. 678 12.00 Open Biotechnology Mar 14th, 2019 12:00AM Mar 14th, 2019 01:45AM Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert® Oral Cancer and OncAlert® Labs product lines include point-of-care and lab-based products that are simple, accurate and cost-effective, and empower healthcare practitioners to improve lives through earlier intervention. The Vigilant Biosciences product line is based on patented technology that measures an unprecedented combination of CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer. The simple, oral rinse procedure is easy to administer and non-invasive for the patient. The OncAlert product line currently includes the OncAlert Labs OraMark Test, the OncAlert Oral Cancer RAPID Test, and the OncAlert Oral Cancer LAB Test. The OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test are both CE Marked and available in select markets outside the United States. OraMark is a laboratory-developed test and will be available in the United States through OncAlert Labs, a CLIA certified laboratory, starting in 2016. Leadership: Matthew H.J. Kim, J.D., Founder Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Sally Bowden, Vice President, Regulatory Affairs, Quality Assurance and Operations Robert T. Hamilton, CPA, Chief Financial Officer Open Biotechnology, Oncology, Diagnostics Open 6301 NW 5th Way, Suite 1550 Ft. Lauderdale FL US 33309 Health Care Equipment & Services
6 private:vigilantbiosciences 9016939 Mar 13th, 2019 12:00AM Vigilant Biosciences, Inc. 678 12.00 Open Biotechnology Mar 13th, 2019 12:00AM Mar 13th, 2019 02:11PM Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert® Oral Cancer and OncAlert® Labs product lines include point-of-care and lab-based products that are simple, accurate and cost-effective, and empower healthcare practitioners to improve lives through earlier intervention. The Vigilant Biosciences product line is based on patented technology that measures an unprecedented combination of CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer. The simple, oral rinse procedure is easy to administer and non-invasive for the patient. The OncAlert product line currently includes the OncAlert Labs OraMark Test, the OncAlert Oral Cancer RAPID Test, and the OncAlert Oral Cancer LAB Test. The OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test are both CE Marked and available in select markets outside the United States. OraMark is a laboratory-developed test and will be available in the United States through OncAlert Labs, a CLIA certified laboratory, starting in 2016. Leadership: Matthew H.J. Kim, J.D., Founder Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Sally Bowden, Vice President, Regulatory Affairs, Quality Assurance and Operations Robert T. Hamilton, CPA, Chief Financial Officer Open Biotechnology, Oncology, Diagnostics Open 6301 NW 5th Way, Suite 1550 Ft. Lauderdale FL US 33309 Health Care Equipment & Services
7 private:vigilantbiosciences 9016939 Mar 12th, 2019 12:00AM Vigilant Biosciences, Inc. 678 12.00 Open Biotechnology Mar 12th, 2019 12:00AM Mar 12th, 2019 08:45AM Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert® Oral Cancer and OncAlert® Labs product lines include point-of-care and lab-based products that are simple, accurate and cost-effective, and empower healthcare practitioners to improve lives through earlier intervention. The Vigilant Biosciences product line is based on patented technology that measures an unprecedented combination of CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer. The simple, oral rinse procedure is easy to administer and non-invasive for the patient. The OncAlert product line currently includes the OncAlert Labs OraMark Test, the OncAlert Oral Cancer RAPID Test, and the OncAlert Oral Cancer LAB Test. The OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test are both CE Marked and available in select markets outside the United States. OraMark is a laboratory-developed test and will be available in the United States through OncAlert Labs, a CLIA certified laboratory, starting in 2016. Leadership: Matthew H.J. Kim, J.D., Founder Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Sally Bowden, Vice President, Regulatory Affairs, Quality Assurance and Operations Robert T. Hamilton, CPA, Chief Financial Officer Open Biotechnology, Oncology, Diagnostics Open 6301 NW 5th Way, Suite 1550 Ft. Lauderdale FL US 33309 Health Care Equipment & Services
8 private:vigilantbiosciences 9016939 Mar 11th, 2019 12:00AM Vigilant Biosciences, Inc. 678 12.00 Open Biotechnology Mar 11th, 2019 12:00AM Mar 11th, 2019 06:18PM Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert® Oral Cancer and OncAlert® Labs product lines include point-of-care and lab-based products that are simple, accurate and cost-effective, and empower healthcare practitioners to improve lives through earlier intervention. The Vigilant Biosciences product line is based on patented technology that measures an unprecedented combination of CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer. The simple, oral rinse procedure is easy to administer and non-invasive for the patient. The OncAlert product line currently includes the OncAlert Labs OraMark Test, the OncAlert Oral Cancer RAPID Test, and the OncAlert Oral Cancer LAB Test. The OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test are both CE Marked and available in select markets outside the United States. OraMark is a laboratory-developed test and will be available in the United States through OncAlert Labs, a CLIA certified laboratory, starting in 2016. Leadership: Matthew H.J. Kim, J.D., Founder Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Sally Bowden, Vice President, Regulatory Affairs, Quality Assurance and Operations Robert T. Hamilton, CPA, Chief Financial Officer Open Biotechnology, Oncology, Diagnostics Open 6301 NW 5th Way, Suite 1550 Ft. Lauderdale FL US 33309 Health Care Equipment & Services
9 private:vigilantbiosciences 9016939 Mar 10th, 2019 12:00AM Vigilant Biosciences, Inc. 677 12.00 Open Biotechnology Mar 10th, 2019 12:00AM Mar 10th, 2019 07:12AM Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert® Oral Cancer and OncAlert® Labs product lines include point-of-care and lab-based products that are simple, accurate and cost-effective, and empower healthcare practitioners to improve lives through earlier intervention. The Vigilant Biosciences product line is based on patented technology that measures an unprecedented combination of CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer. The simple, oral rinse procedure is easy to administer and non-invasive for the patient. The OncAlert product line currently includes the OncAlert Labs OraMark Test, the OncAlert Oral Cancer RAPID Test, and the OncAlert Oral Cancer LAB Test. The OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test are both CE Marked and available in select markets outside the United States. OraMark is a laboratory-developed test and will be available in the United States through OncAlert Labs, a CLIA certified laboratory, starting in 2016. Leadership: Matthew H.J. Kim, J.D., Founder Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Sally Bowden, Vice President, Regulatory Affairs, Quality Assurance and Operations Robert T. Hamilton, CPA, Chief Financial Officer Open Biotechnology, Oncology, Diagnostics Open 6301 NW 5th Way, Suite 1550 Ft. Lauderdale FL US 33309 Health Care Equipment & Services
10 private:vigilantbiosciences 9016939 Mar 9th, 2019 12:00AM Vigilant Biosciences, Inc. 677 12.00 Open Biotechnology Mar 9th, 2019 12:00AM Mar 9th, 2019 06:01PM Vigilant Biosciences is a leading innovator and developer of solutions that aid in the early detection and intervention of cancer. The Vigilant Biosciences OncAlert® Oral Cancer and OncAlert® Labs product lines include point-of-care and lab-based products that are simple, accurate and cost-effective, and empower healthcare practitioners to improve lives through earlier intervention. The Vigilant Biosciences product line is based on patented technology that measures an unprecedented combination of CD44, a tumor-initiating and stem cell-associated biomarker, and total protein levels – markers clinically validated to be associated specifically with oral cancer when measured in an oral rinse – to aid clinicians in the early detection and intervention of oral cancer. The simple, oral rinse procedure is easy to administer and non-invasive for the patient. The OncAlert product line currently includes the OncAlert Labs OraMark Test, the OncAlert Oral Cancer RAPID Test, and the OncAlert Oral Cancer LAB Test. The OncAlert Oral Cancer RAPID Test and the OncAlert Oral Cancer LAB Test are both CE Marked and available in select markets outside the United States. OraMark is a laboratory-developed test and will be available in the United States through OncAlert Labs, a CLIA certified laboratory, starting in 2016. Leadership: Matthew H.J. Kim, J.D., Founder Elizabeth Franzmann, M.D., Scientific Founder and Chief Scientific Officer Michael Donovan, M.D. Ph.D., Chief Clinical Officer Sally Bowden, Vice President, Regulatory Affairs, Quality Assurance and Operations Robert T. Hamilton, CPA, Chief Financial Officer Open Biotechnology, Oncology, Diagnostics Open 6301 NW 5th Way, Suite 1550 Ft. Lauderdale FL US 33309 Health Care Equipment & Services

Showing a preview of 94 rows

Get a demo to see more examples from the Linkedin Profile dataset.